Navigation Links
Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma
Date:6/7/2011

mes for our injured personnel, and assist in their healthy recovery to active duty."

The Magellan® system is an FDA 510(k) cleared medical device for the rapid production of platelet rich plasma from blood and bone marrow that is applied to a surgical site as surgeons deem necessary for their clinical use requirements. Magellan MAR01™ technology enables the rapid "closed system" concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells and mesenchymal stem cells, commonly viewed as key components in tissue repair. The self contained Magellan unit provides critical ease-of-use and operator-independent consistency necessary for deployment in military medical operations. In addition to therapies for battlefield wounds, Arteriocyte is currently enrolling patients into an FDA approved Phase I IDE clinical trial to evaluate the role of MAR01™ in peripheral vascular disease (critical limb ischemia) with additional cardiac and orthopedic trials planned.

The NANEX™ platform consists of a biofunctional nanofiber-based 3D scaffold designed to mimic the bone marrow environment, permitting rapid ex vivo proliferation of hematopoietic stem cells with minimal differentiation. Arteriocyte has multiple active development programs for its NANEX technology including treatment of ischemic disease, identification and treatment of cancers of the blood system and rapid high volume ex vivo red blood cell production.

Arteriocyte CEO Don Brown said, "We consider it a privilege to be requested by the U.S. Military to help in the care delivery for our men and women in uniform. We strongly believe it is our responsibility to make Arteriocyte's technologies available to those who volunteer to serve our country, and we are humbled by the opportunity to work with our partners at Fort Sam Houston to help ensure that our wounded soldiers get access to the best care possible so they can g
'/>"/>

SOURCE Arteriocyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
2. Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010
3. Ontario Institute for Cancer Research Announces Spin Off Companies Developing Promising Anticancer Technologies
4. Ludwig Institute for Cancer Research and Polaris Group Form Collaboration to Expand Development of Polaris Novel Cancer Drug, ADI-PEG 20
5. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
6. Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium
7. Van Andel Institute Earns Highest "Green Building" Award
8. LifeNet Health Breaks Ground on New Institute of Regenerative Medicine
9. The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting
10. MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
11. IBM and The Institute of Bioengineering and Nanotechnology Find Breakthrough for MRSA Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... A recent study from researchers in Tasmania ... that those who took probiotics were able to run for ... showed that in extreme heat conditions, probiotics were able to ... acne treatment explains what this new discovery means for ... skin condition. , While researchers tote the benefits of ...
(Date:5/21/2013)... YORK , May 21, 2013  The Lindsley F. ... today that it is a Grand Challenges Explorations ... Gates Foundation .  Dr. Sara Lustigman , ... innovative global health and development research project, titled Innovative ...  These worms are needed to screen drugs to help ...
(Date:5/21/2013)... 2013 The congress of the ... is the biggest congress in Europe ... participants are in Istanbul to ... New pioneering studies have been presented: / ... ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" By ...
(Date:5/21/2013)... May 21, 2013 As the ... strong push within the industry to deliver better ... Organizations and pharma companies often means turning big ... Microtablets, developed in collaboration with Sensidose AB and ... can bring products to market sooner. The partnership ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2
... Therapeutics Inc.,(Lorus), a biopharmaceutical company specializing in the research ... cancer, today reported financial results for the three and ... amounts are in Canadian,dollars., 2008 HIGHLIGHTS, ... Lorus, lead anticancer small ...
... N.J., July 21 Schering-Plough,Corporation (NYSE: SGP ... call and,webcast to review the sales and earnings ... p.m. (EDT) from 8 a.m. today. The quarterly,financial ... after the close of,the New York Stock Exchange., ...
... Limited (TSX: GEN),a company focused on developing ... diseases and personalized health management, today announced,the ... molecular test,for colorectal cancer screening. ColonSentry(TM) is ... risk of having colorectal cancer, identifying,those in ...
Cached Biology Technology:Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 2Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 3Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 4Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 5Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 6Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 7Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 8Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today 2GeneNews launches world's first blood test for colorectal cancer screening 2GeneNews launches world's first blood test for colorectal cancer screening 3
(Date:5/21/2013)... Cancers of all types become most deadly when ... cancer has reached this stage, it becomes very difficult ... that can develop. Now, researchers at the University of ... that target lymphoma tumor cells wherever they may be ... oncology in the MU College of Veterinary Medicine, says ...
(Date:5/21/2013)... the world,s largest scientific society, invites news media ... September 8-12, 2013, in Indianapolis, Ind. It will ... at area hotels. , With more than 7,100 ... from astronomy to zoology ― the meeting ... rich assortment of spot news and feature possibilities. ...
(Date:5/21/2013)... genes function without changing the underlying DNA sequence, ... pregnant women during any trimester, potentially providing a ... after giving birth, and an opportunity to intervene ... the small study involving 52 pregnant women are ... . , "Postpartum depression can be harmful to ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... CA] A new study, led by PRBO Conservation Science ... marshes under high-end sea-level rise scenarios that are increasingly likely. ... scenario 93% of San Francisco Bay,s tidal marsh could be ... 1.65 meters of sea-level rise, low sediment availability and no ...
... centuries that many bacteria produce hydrogen sulfide (H2S) it was ... Now, researchers at NYU School of Medicine have discovered ... from the effects of numerous different antibiotics. In ... Anderson Professor of Biochemistry at NYU School of Medicine, researchers ...
... BLACKSBURG, VA -- Many landscape trees are started in-ground, ... them in large containers to grow. To minimize wind ... growing beds, the liners are often buried deeper than ... container plants with deep structural roots, important foundations of ...
Cached Biology News:Bleak future for Bay area tidal marshes? 2Bleak future for Bay area tidal marshes? 3Bleak future for Bay area tidal marshes? 4Targeting bacterial gas defenses allow for increased efficacy of numerous antibiotics 2Planting depth's effect on container-grown trees 2
... The loxP-cm-loxP cassette ... in prokaryotic cells. The prokaryotic ... chloramphenicol resistance is a slightly modified ... mediates higher transcription efficiency than the ...
... Agencourt AMPure is a magnetic ... requires no sample transfer, centrifugation ... purifies small and large PCR ... 384-well microplates. Agencourt AMPure can ...
... a magnetic bead-based PCR purification ... transfer, centrifugation or filtration steps. ... large PCR extension products in ... AMPure can easily be performed ...
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
Biology Products: